Novel potassium channel activators: Synthesis and structure-activity relationship studies of 3,4-dihydro-2H-1,4-benzoxazine derivatives

Chemical and Pharmaceutical Bulletin

Volumn 44, Issue 1, 1996, Pages 103-114

  Matsumoto, Yuzo ^a   Tsuzuki, Ryuji ^a   Matsuhisa, Akira ^a   Takayama, Kazuhisa ^a   Yoden, Toru ^a   Uchida, Wataru ^a   Asano, Masaharu ^a   Fujita, Shigeo ^a   Yanagisawa, Isao ^a   Fujikura, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

3,4 dihydro 2H 1,4 benzoxazine; antihypertensive effect; cromakalim; potassium channel activator

Indexed keywords

2 (3,4 DIHYDRO 2,2 DIMETHYL 6 NITRO 2H 1,4 BENZOXAZIN 4 YL)PYRIDINE 1 OXIDE; 3,4 DIHYDRO 2H 1,4 BENZOXAZINE DERIVATIVE; CROMAKALIM; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONFORMATIONAL TRANSITION; DOG; DRUG CONFORMATION; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STRUCTURE ACTIVITY RELATION;

EID: 13344286316     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.44.103     Document Type: Article

References (23)

1. For reviews of potassium channel activators, see: a) Cook N. S., Trends Pharmacol. Sci., 9, 21 (1988); b) Robertson D. W., Steinberg M. I., Ann. Reports Med. Chem., 1989, 91; c) Quast U., Cook N. S., Trends Pharmacol. Sci., 10, 431 (1989); d) Robertson D. W., Steinberg M. I., J. Med. Chem., 33, 1529 (1990); e) Edwards G., Weston A. H., Trends Pharmacol. Sci., 11, 417 (1990); f) Evans J M., Longman S. D., Ann. Reports Med. Chem., 1991, 73, g) Longman S. D., Hamilton T. C., Med. Res. Rev., 12, 73 (1992).
2. For reviews of potassium channel activators, see: a) Cook N. S., Trends Pharmacol. Sci., 9, 21 (1988); b) Robertson D. W., Steinberg M. I., Ann. Reports Med. Chem., 1989, 91; c) Quast U., Cook N. S., Trends Pharmacol. Sci., 10, 431 (1989); d) Robertson D. W., Steinberg M. I., J. Med. Chem., 33, 1529 (1990); e) Edwards G., Weston A. H., Trends Pharmacol. Sci., 11, 417 (1990); f) Evans J M., Longman S. D., Ann. Reports Med. Chem., 1991, 73, g) Longman S. D., Hamilton T. C., Med. Res. Rev., 12, 73 (1992).
3. For reviews of potassium channel activators, see: a) Cook N. S., Trends Pharmacol. Sci., 9, 21 (1988); b) Robertson D. W., Steinberg M. I., Ann. Reports Med. Chem., 1989, 91; c) Quast U., Cook N. S., Trends Pharmacol. Sci., 10, 431 (1989); d) Robertson D. W., Steinberg M. I., J. Med. Chem., 33, 1529 (1990); e) Edwards G., Weston A. H., Trends Pharmacol. Sci., 11, 417 (1990); f) Evans J M., Longman S. D., Ann. Reports Med. Chem., 1991, 73, g) Longman S. D., Hamilton T. C., Med. Res. Rev., 12, 73 (1992).
4. For reviews of potassium channel activators, see: a) Cook N. S., Trends Pharmacol. Sci., 9, 21 (1988); b) Robertson D. W., Steinberg M. I., Ann. Reports Med. Chem., 1989, 91; c) Quast U., Cook N. S., Trends Pharmacol. Sci., 10, 431 (1989); d) Robertson D. W., Steinberg M. I., J. Med. Chem., 33, 1529 (1990); e) Edwards G., Weston A. H., Trends Pharmacol. Sci., 11, 417 (1990); f) Evans J M., Longman S. D., Ann. Reports Med. Chem., 1991, 73, g) Longman S. D., Hamilton T. C., Med. Res. Rev., 12, 73 (1992).
5. For reviews of potassium channel activators, see: a) Cook N. S., Trends Pharmacol. Sci., 9, 21 (1988); b) Robertson D. W., Steinberg M. I., Ann. Reports Med. Chem., 1989, 91; c) Quast U., Cook N. S., Trends Pharmacol. Sci., 10, 431 (1989); d) Robertson D. W., Steinberg M. I., J. Med. Chem., 33, 1529 (1990); e) Edwards G., Weston A. H., Trends Pharmacol. Sci., 11, 417 (1990); f) Evans J M., Longman S. D., Ann. Reports Med. Chem., 1991, 73, g) Longman S. D., Hamilton T. C., Med. Res. Rev., 12, 73 (1992).
6. For reviews of potassium channel activators, see: a) Cook N. S., Trends Pharmacol. Sci., 9, 21 (1988); b) Robertson D. W., Steinberg M. I., Ann. Reports Med. Chem., 1989, 91; c) Quast U., Cook N. S., Trends Pharmacol. Sci., 10, 431 (1989); d) Robertson D. W., Steinberg M. I., J. Med. Chem., 33, 1529 (1990); e) Edwards G., Weston A. H., Trends Pharmacol. Sci., 11, 417 (1990); f) Evans J M., Longman S. D., Ann. Reports Med. Chem., 1991, 73, g) Longman S. D., Hamilton T. C., Med. Res. Rev., 12, 73 (1992).
7. For reviews of potassium channel activators, see: a) Cook N. S., Trends Pharmacol. Sci., 9, 21 (1988); b) Robertson D. W., Steinberg M. I., Ann. Reports Med. Chem., 1989, 91; c) Quast U., Cook N. S., Trends Pharmacol. Sci., 10, 431 (1989); d) Robertson D. W., Steinberg M. I., J. Med. Chem., 33, 1529 (1990); e) Edwards G., Weston A. H., Trends Pharmacol. Sci., 11, 417 (1990); f) Evans J M., Longman S. D., Ann. Reports Med. Chem., 1991, 73, g) Longman S. D., Hamilton T. C., Med. Res. Rev., 12, 73 (1992).
8. Ashwood V. A., Buckingham R. E., Cassidy F., Evans J. M., Faruk E. A., Hamilton T. C., Nash D. J., Stemp G., Willcocks K., J. Med. Chem., 33, 1529 (1990).
9. Peterson H. J., Nielsen C. K., Martelli E. A., J. Med. Chem., 21, 773 (1978).
10. Sakai K., Jpn. J. Pharmacol., 30, 881 (1980).
11. Brown T. J., Chapman R. F., Cook D. C., Hart T. W., Mclay I. M., Jordan R., Mason J. S., Palfreyman M. N., Walsh R. J. A., Withnall M. T., Aloup J. C., Cavero I., Farge D., James C., Mondot S., J. Med. Chem., 35, 3613 (1992).
12. a) Smith D. G., Stemp G., Japan. Patent 211584 (1989) [Chem. Abstr., 112, 55610k (1990);
13. b) Ashwood V. A., Cassidy F., Evans J. M., Gagliardi S., Stemp G., J. Med. Chem., 34, 3261 (1991).
14. Bergmann R., Gericke R., J. Med. Chem., 33, 492 (1990).
15. Newbery G., Phillips M. A., J. Chem. Soc., 1928, 3046.
16. Shrider D. R., Gandhi S. S , Rao K. S., Synthesis, 1982, 986.
17. Ellis G. P., Romney-Alexander T. M., Chem. Rev., 87, 779 (1987).
18. 1H-NMR a nuclear Overhauser effect (NOE) was observed between cis hydrogen atoms.
19. 1H-NMR no NOE was observed between trans hydrogen atoms.
20. Ochiai E., Itai I., Yoshino K., Proc. Imp. Acad. (Tokyo), 20, 141 (1944).
21. Uchida Y., Sugimoto T., Myakkangaku, 24, 133 (1984).
22. Hamilton T. C., Weir S. W., Weston A. H., Br. J. Pharmacol., 88, 103 (1986).
23. Cavero I., Mondot S., Mestre M., J. Pharmacol. Exp Ther., 248, 1261 (1989).